LXEO — Lexeo Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Lexeo Therapeutics Announces $80 Million Equity Financing
Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Lexeo Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data For Lx2006 In Friedreich Ataxia Cardiomyopathy Supporting Advancement To Registrational Study
U.S. RESEARCH ROUNDUP-Finance of America Companies, SM Energy, Verizon
Brief: Lexeo Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $75 Million - SEC Filing
Brief: Lexeo Therapeutics Appoints Kyle Rasbach As CFO
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Lexeo rises on alignment with FDA on development plan for gene therapy
Brief: Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference
U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix
U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics
Brief: Lexeo Therapeutics Announces License Agreement To Accelerate Development Of LX2006
U.S. STOCKS ON THE MOVE-US Health Insurers, Palisade Bio, Dynatronics
Lexeo Therapeutics rises after receiving fast track tag for gene therapy
Brief: Lexeo Therapeutics Granted FDA Fast Track Designation For LX2006
Brief: Lexeo Therapeutics Files For Resale Of Up To 6.97 Mln Shares By Selling Stockholders
Brief: Lexeo Therapeutics Announces Closing Of Oversubscribed $95.0 Million Equity Financing